PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

16th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 11th May 2022 (Educational supporters)

Keynote: PCSK9 gene variants – An update

Keynote: PCSK9 gene variants – An update

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Marianne Abi-Fadel

Posted on 27 June 2022 | Posted by Marianne Abi-Fadel | Posted in Hot topics, 16th Closed Scientific Expert Meeting of the Editorial Board

Oral PCSK9 inhibitors: New horizons

Oral PCSK9 inhibitors: New horizons

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Douglas Johns

Posted on 7 July 2022 | Posted by Douglas Johns | Posted in 16th Closed Scientific Expert Meeting of the Editorial Board

PCSK9 inhibitors in type 2 diabetes: New insights from clinical trials and epidemiologic and genetic data

PCSK9 inhibitors in type 2 diabetes: New insights from clinical trials and epidemiologic and genetic data

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Lawrence Leiter

Posted on 27 June 2022 | Posted by Lawrence Leiter | Posted in Hot topics, 16th Closed Scientific Expert Meeting of the Editorial Board

Is PCSK9 a player in remnant lipoprotein metabolism?

Is PCSK9 a player in remnant lipoprotein metabolism?

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Elias Bjornson

Posted on 7 July 2022 | Posted by Elias Bjornson | Posted in 16th Closed Scientific Expert Meeting of the Editorial Board

Statin intolerance: Do we need a new clinical definition and management strategies? Setting the scene, Europe

Statin intolerance: Do we need a new clinical definition and management strategies? Setting the scene, Europe

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Ulrich Laufs

Posted on 26 July 2022 | Posted in 16th Closed Scientific Expert Meeting of the Editorial Board

Statin intolerance: Do we need a new clinical definition and management strategies? Setting the scene, USA

Statin intolerance: Do we need a new clinical definition and management strategies? Setting the scene, USA

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Paul Thompson

Posted on 26 July 2022 | Posted by Paul Thompson | Posted in 16th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved